Fresenius SE Earnings Call Highlights Growth Momentum

Fresenius Se ((FSNUY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Fresenius SE’s latest earnings call struck an upbeat tone, with management emphasizing strong organic growth, double‑digit core EPS expansion, and robust cash generation. Executives acknowledged regulatory and pricing headwinds, but argued that momentum in Kabi and Biopharma plus rapid deleveraging give the group more flexibility to absorb macro and competitive risks.

Upgraded Growth Delivered on Revenue and EBIT

Fresenius closed the year by hitting upgraded targets, reporting 7% organic revenue growth and 6% EBIT growth at constant currency. Management framed this as evidence that the reshaped portfolio is now delivering more predictable performance, even in a choppy macro environment.

Core EPS Expansion Underpins Renewed Confidence

Core EPS rose 12% for FY2025, marking a second straight year of double‑digit growth and signaling improving earnings quality. For 2026, the company now guides core EPS growth of 5%–10%, indicating confidence in sustaining profit gains despite mounting cost and pricing pressures.

Cash Generation Fuels Deleveraging

Operating cash flow in Q4 topped EUR 1.3 billion, driving a full‑year cash conversion of 1.1 across the group, including 1.2 at Helios and 1.0 at Kabi. This helped Fresenius cut net debt by about EUR 3 billion over two years, bringing leverage down to 2.7x EBITDA, within its 2.5–3x corridor.

Dividend Lift Signals Strength for Shareholders

Reflecting the stronger balance sheet and earnings trajectory, the company proposed a 5% dividend increase to EUR 1.05 per share for FY2025. Management portrayed the higher payout as evidence that Fresenius can both invest for growth and return more cash to investors.

Kabi Delivers Strong Momentum and Margin Upgrade

Kabi posted 10% organic growth in Q4, its strongest quarter in absolute revenue, with growth vectors up 16% and Biopharma soaring 97%. The unit expanded growth‑vector margins by 130 basis points and raised its structural EBIT margin ambition to 17%–19%, with 2026 guidance of 16.5%–17%.

Biopharma Wins Market Share in Key Launches

In biosimilars, Tyenne emerged as the fastest‑growing product in its class, capturing about 37% share in EU4 plus the U.K. and roughly 17% in the U.S. Fresenius also secured over 100 U.S. contracts for its denosumab biosimilar, while Otulfi uptake is supported by new presentations and regulatory milestones.

Helios Shows Progress but Needs More Work

Helios delivered 8% organic growth in Q4, with Germany up 6% and Spain up 11%, and achieved an EBIT margin of 11.7%, including nearly 15% in Spain. Management credited performance programs and a temporary 3.25% surcharge but stressed that Helios, especially Germany, must still step up structurally.

MedTech and Nutrition Build on Platform Rollouts

MedTech and Nutrition posted mid‑single‑digit organic growth in Q4, each up about 5%, supporting the diversification story beyond core pharma. The Ivenix infusion platform rollout is expected to become a significant MedTech growth driver in 2026 as deployments scale across key markets.

Macro and Regulatory Volatility Remains a Wildcard

Management flagged ongoing geopolitical and macro uncertainty, pointing to recent tariff rulings and evolving PBM reforms as notable swing factors. They cautioned that current guidance cannot fully capture these risks and that unchanged FX spot rates could trim reported figures by roughly 1%.

Helios Structural Efficiency Still Under Scrutiny

Despite better Q4 numbers, executives conceded that Helios Germany still falls short of internal expectations on efficiency and profitability. The current performance program is set to continue, with an explicit goal of sustaining margins once temporary surcharge benefits expire.

Managing Ongoing Price Pressure in Pharma

The company expects continued single‑digit to mid‑single‑digit price erosion across its pharma portfolio, noting that Q4 pressures were particularly pronounced. Fresenius plans to offset this through volume growth, reliable supply, and product mix, rather than banking on any pricing relief.

China Nutrition Faces Targeted Headwinds

Nutrition growth was held back by volume‑based procurement for Keto products in China, which weighed on regional performance. Management aims to mitigate this by focusing on segments outside the tendered VBP business and pushing growth in other geographies and product lines.

Competition Intensifies in Biosimilars

While Biopharma grew a striking 97% in Q4, executives warned that such growth rates will be hard to sustain as new competitors enter biosimilar markets. The strategy is to defend share with strong execution and carefully manage pricing to balance volume and profitability.

Rising Corporate Costs Clip Margin Upside

Analysts questioned an uptick in corporate costs that partially offsets operating margin expansion at the group level. Fresenius attributed this to ramp‑up investments and corporate projects that will weigh on reported margins in the near term but are framed as necessary for future growth.

Tax and Timing Effects Distort Q4 Optics

The Q4 tax rate moved higher due to provisions in income tax liabilities, creating some noise in after‑tax figures. Management also flagged timing effects from payer settlements and the treatment of surcharges under other income, which impacted quarterly phasing but not full‑year trends.

Guidance Points to Steady Growth and Margin Ambition

For 2026, Fresenius guides to 4%–7% group organic revenue growth and 5%–10% core EPS growth at constant currency, targeting an EBIT margin around 11.5%. Kabi is seen growing mid‑ to high‑single digits with a 16.5%–17% margin, while Helios is guided to mid‑single‑digit growth and a 10%–10.5% margin, supported by ongoing surcharges and disciplined CapEx and leverage.

Fresenius’s call painted a picture of a company exiting restructuring with clearer growth engines and a stronger balance sheet, even as it faces regulatory and pricing pressures. For investors, the story now hinges on Kabi and Biopharma sustaining their pace, Helios closing its structural gap, and management converting guidance into consistent, high‑quality earnings.